HomeREGULATORY
REGULATORY

Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
(Jun.14.2018)

Japan’s health ministry has added MSD’s immuno-oncology agent Keytruda (pembrolizumab) and Pfizer’s breast cancer drug Ibrance (palbociclib) to a list of products subject to economic evaluations under its pilot-based cost-effective assessment (CEA) program ...
(LOG IN FOR FULL STORY)

News Calendar